

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

WinNonlin

RRID:SCR_024504

Type: Tool

Proper Citation

WinNonlin (RRID:SCR_024504)

Resource Information

URL: <https://www.certara.com/software/phoenix-pkpd/>

Proper Citation: WinNonlin (RRID:SCR_024504)

Description: Software to automate repetitive analysis steps and is widely considered the industry standard for NCA, TK, and PK/PD modeling. Used as non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling tool.

Synonyms: Phoenix WinNonlin

Resource Type: software application, software resource

Keywords: automate repetitive analysis steps, NCA, TK, PK/PD modeling, non-compartmental analysis, pharmacokinetic/pharmacodynamic, toxicokinetic, modeling tool,

Resource Name: WinNonlin

Resource ID: SCR_024504

Record Creation Time: 20231002T161336+0000

Record Last Update: 20260905T133318+0000

Ratings and Alerts

No rating or validation information has been found for WinNonlin.

No alerts have been found for WinNonlin.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2013 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Koyama T, et al. (2026) A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. Investigational new drugs.

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. Molecular cancer therapeutics, 25(7), 1157.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Wei X, et al. (2026) Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. Cancer discovery, 16(6), 1152.

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. Molecular cancer therapeutics.

Hoch M, et al. (2026) Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants. Clinical pharmacology in drug development, 15(2), e1611.

Jacobs ME, et al. (2026) Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations. Drug testing and analysis, 18(1), 139.

Zhang CX, et al. (2026) Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. Clinical and translational science, 19(1), e70453.

Seefried L, et al. (2026) A randomized Phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 41(3), 231.

Gareau A, et al. (2026) Serum Symmetric Dimethylarginine as a Predictor of Toxicity of Carboplatin in Dogs. Veterinary and comparative oncology, 24(1), 140.

Fabbrini E, et al. (2026) Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers. The Journal of clinical endocrinology and metabolism, 111(6), 1628.

Kancharla P, et al. (2026) Potent acridone antimalarial against all three life stages of Plasmodium. Nature communications, 17(1).

Shuang Q, et al. (2026) Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta. mAbs, 18(1), 2657099.

Wu Q, et al. (2026) Pharmacokinetics of Lekethromycin in Swine Following Intramuscular Administration at Different Doses with a Single Intravenous Reference Dose for Absolute Bioavailability and Matrix Comparison. *Veterinary sciences*, 13(3).

Wu B, et al. (2026) Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. *Journal of medicinal chemistry*, 69(8), 9348.

Xiong L, et al. (2026) Orthosteric-allosteric dual inhibitors of PI5P4K?? with potent antitumor activity in non-small cell lung cancer. *Journal of advanced research*, 84, 1105.

Youssef AS, et al. (2026) A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. *Clinical pharmacology in drug development*, 15(2), e1615.

Op 't Hoog CJP, et al. (2026) Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. *British journal of clinical pharmacology*, 92(4), 1117.

Otani Y, et al. (2026) One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants. *Advances in therapy*, 43(1), 377.

Wang Y, et al. (2026) Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A. *NPJ systems biology and applications*, 12(1).